<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941202-0-00031</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (c) * * *  <!-- PJG 0012 frnewline --> (2) Patient's or human research subject's name, and identification number if one has been assigned;  <!-- PJG 0012 frnewline --> (3) Prescribed dosage and activity of the dosage at the time of measurement, or a notation that the total activity is less than 1.1 megabecquerels (30 microcuries);  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 29. In &sect;35.60, paragraphs (b) and (c) are revised to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.60  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Syringe shields and labels.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b) To identify its contents, a licensee shall conspicuously label each syringe or syringe radiation shield that contains a syringe with a radiopharmaceutical. The label must show the radiopharmaceutical name or its abbreviation, the clinical procedure to be performed, or the patient's or the human research subject's name.  <!-- PJG 0012 frnewline --> (c) A licensee shall require each individual who prepares a radiopharmaceutical kit to use a syringe radiation shield when preparing the kit and shall require each individual to use a syringe radiation shield when administering a radiopharmaceutical by injection unless the use of the shield is contraindicated for that patient or human research subject.  <!-- PJG 0012 frnewline --> 30. Section 35.75 is revised to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.75  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Release of patients or human research subjects containing radiopharmaceuticals or permanent implants.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a) A licensee may not authorize release from confinement for medical care any patient or human research subject administered a radiopharmaceutical until either:  <!-- PJG 0012 frnewline --> (1) The measured dose rate from the patient or the human research subject is less than 5 millirems per hour at a distance of 1 meter; or  <!-- PJG 0012 frnewline --> (2) The activity in the patient or the human research subject is less than 30 millicuries.  <!-- PJG 0012 frnewline --> (b) A licensee may not authorize release from confinement for medical care of any patient or human research subject administered a permanent implant until the measured dose rate from the patient or the human research subject is less than 5 millirems per hour at a distance of 1 meter.  <!-- PJG 0012 frnewline --> 31. Section 35.100 is revised to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.100  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Use of unsealed byproduct material for uptake, dilution, and excretion studies.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A licensee may use for uptake, dilution, or excretion studies any unsealed byproduct material prepared for medical use that is either:  <!-- PJG 0012 frnewline --> (a) Obtained from a manufacturer or preparer licensed pursuant to 10 CFR 32.72 or equivalent Agreement State requirements; or  <!-- PJG 0012 frnewline --> (b) Prepared by an authorized nuclear pharmacist, a physician who is an authorized user and who meets the requirements specified in &sect;35.920, or an individual under the supervision of either as specified in &sect;35.25.  <!-- PJG 0012 frnewline --> 32. Section 35.200 is revised to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.200  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Use of unsealed byproduct material for imaging and localization studies.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A licensee may use for imaging and localization studies any unsealed byproduct material prepared for medical use that is either:  <!-- PJG 0012 frnewline --> (a) Obtained from a manufacturer or preparer licensed pursuant to 10 CFR 32.72 or equivalent Agreement State requirements; or  <!-- PJG 0012 frnewline --> (b) Prepared by an authorized nuclear pharmacist, a physician who is an authorized user and who meets the requirements specified in &sect;35.920, or an individual under the supervision of either as specified in &sect;35.25.  <!-- PJG 0012 frnewline --> 33. Section 35.300 is revised to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;35.300  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Use of unsealed byproduct material for therapeutic administration.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A licensee may use for therapeutic administration any unsealed byproduct material prepared for medical use that is either:  <!-- PJG 0012 frnewline --> (a) Obtained from a manufacturer or preparer licensed pursuant to 10 CFR 32.72 or equivalent Agreement State requirements; or  <!-- PJG 0012 frnewline --> (b) Prepared by an authorized nuclear pharmacist, a physician who is an authorized user and who meets the requirements specified in &sect;35.920, or an individual under the supervision of either as specified in &sect;35.25.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            